AU2002331927A1 - Benzothiazepine derivatives for the treatment of hyperlipidaemia - Google Patents

Benzothiazepine derivatives for the treatment of hyperlipidaemia

Info

Publication number
AU2002331927A1
AU2002331927A1 AU2002331927A AU2002331927A AU2002331927A1 AU 2002331927 A1 AU2002331927 A1 AU 2002331927A1 AU 2002331927 A AU2002331927 A AU 2002331927A AU 2002331927 A AU2002331927 A AU 2002331927A AU 2002331927 A1 AU2002331927 A1 AU 2002331927A1
Authority
AU
Australia
Prior art keywords
formula
solvate
alkyl
salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002331927A
Other versions
AU2002331927B2 (en
Inventor
David Blomberg
Mikael Ulf Johan Dahlstrom
Ingemar Starke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albireo AB
Original Assignee
Albireo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0121621.7A external-priority patent/GB0121621D0/en
Application filed by Albireo AB filed Critical Albireo AB
Publication of AU2002331927A1 publication Critical patent/AU2002331927A1/en
Application granted granted Critical
Publication of AU2002331927B2 publication Critical patent/AU2002331927B2/en
Assigned to ALBIREO AB reassignment ALBIREO AB Request for Assignment Assignors: ASTRAZENECA AB
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Description

BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPΞR IPIDEMIA
This invention relates to benzothiazepine derivatives, or pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof. These benzothiazepines possess ileal bile acid transport (IBAT) inhibitory activity and accordingly have value in the treatment of disease states associated with hyperlipidaemic conditions and they are useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said benzothiazepine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit IBAT in a warm-blooded animal, such as man.
It is well-known that hyperlipidaemic conditions associated with elevated concentrations of total cholesterol and low-density lipoprotein cholesterol are major risk factors for cardiovascular atherosclerotic disease (for instance "Coronary Heart Disease: Reducing the Risk; a Worldwide View" Assman G., Carmena R. Cullen P. et al; Circulation 1999, 100, 1930-1938 and "Diabetes and Cardiovascular Disease: A Statement for Healthcare Professionals from the American Heart Association" Grundy S, Benjamin L, Burke G., et al; Circulation, 1999, 100, 1134-46). Interfering with the circulation of bile acids within the lumen of the intestinal tracts is found to reduce the level of cholesterol. Previous established therapies to reduce the concentration of cholesterol involve, for instance, treatment with HMG-CoA reductase inhibitors, preferably statins such as simvastatin and fluvastatin, or treatment with bile acid binders, such as resins. Frequently used bile acid binders are for instance cholestyramine and cholestipol. One recently proposed therapy ("Bile Acids and Lipoprotein Metabolism: a Renaissance for Bile Acids in the Post Statin Era" Angelin B, Eriksson M, Rudling M; Current Opinion on Lipidology, 1999, 10, 269-74) involved the treatment with substances with an IBAT inhibitory effect.
Re-absorption of bile acid from the gastro-intestinal tract is a normal physiological process which mainly takes place in the ileum by the IBAT mechanism. Inhibitors of IBAT can be used in the treatment of hypercholesterolaemia (see for instance "Interaction of bile acids and cholesterol with nonsystemic agents having hypocholesterolaemic properties", Biochemica et Biophysica Acta, 1210 (1994) 255- 287). Thus, suitable compounds having such inhibitory IBAT activity are also useful in the treatment of hyperlipidaemic conditions. Compounds possessing such IBAT inhibitory activity have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/38182, WO 99/35135, WO 98/40375, WO 99/35153, WO 99/64409, WO 99/64410, WO 00/01687, WO 00/47568, WO 00/61568, WO 01/68906, DE 19825804, WO 00/38725, WO 00/38726, WO 00/38727, WO 00/38728, WO 00/38729, WO 01/68906, WO 01/66533, WO 02/50051 and EP 0 864 582.
A further aspect of this invention relates to the use of the compounds of the invention in the treatment of dyslipidemic conditions and disorders such as hyperlipidaemia, hypertrigliceridemia, hyperbetalipoproteinemia (high LDL), hyperprebetalipoproteinemia (high NLDL), hyperchylomicronemia, hypolipoproteinemia, hypercholesterolemia, hyperlipoproteinemia and hypoalphalipoproteinemia (low HDL), addition, these compounds are expected to be useful for the prevention and treatment of different clinical conditions such as atherosclerosis, arteriosclerosis, arrhythmia, hyper-thrombotic conditions, vascular dysfunction, endothelial dysfunction, heart failure, coronary heart diseases, cardiovascular diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, inflammation of cardiovascular tissues such as heart, valves, vasculature, arteries and veins, aneurisms, stenosis, restenosis, vascular plaques, vascular fatty streaks, leukocytes, monocytes and/or macrophage infiltration, intimal thickening, medial thinning, infectious and surgical trauma and vascular thrombosis, stroke and transient ischaemic attacks.
The present invention is based on the discovery that certain benzothiazepine compounds surprisingly inhibit IBAT. Such properties are expected to be of value in the treatment of disease states associated with hyperlipidaemic conditions.
Accordingly, the present invention provides a compound of formula (I):
(I) wherein:
One of R1 and R2 are selected from hydrogen, C1-6alkyl or C -6alkenyl and the other is selected from C1-6alkyl or C2-6alkenyl; Ry is selected from hydrogen, hydroxy, C1-6alkyl, C1-4alkoxy and C1-6alkanoyloxy;
Kz is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl) carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(Cι-6alkyl)sulphamoyl and N,N-(C1-6alkyl)2sulphamoyl; v is 0-5; one of R4 and R5 is a group of formula (IA):
(IA)
R3 and R6 and the other of R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2- alkenyl, C2- alkynyl, C^alkoxy, C1- alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl,
N-(C1- alkyl)sulphamoyl and N, N-(C1-4alkyl)2sulphamoyl; wherein R3 and R6 and the other of R4 and R5 may be optionally substituted on carbon by one or more R1 ;
X is -O-, -Ν(Ra)-, -S(O)b- or -CH(R )-; wherein Ra is hydrogen or C1-6alkyl and b is 0- 2; Ring A is aryl or heteroaryl; wherein Ring A is optionally substituted by one or more substituents selected from R17;
R7 is hydrogen, C1- alkyl, carbocyclyl or heterocyclyl; wherein R7 is optionally substituted by one or more substituents selected from R ; R8 is hydrogen or C1-4alkyl; R9 is hydrogen or C1- alkyl;
R10 is hydrogen, C1-4alkyl, carbocyclyl or heterocyclyl; wherein R10 is optionally substituted by one or more substituents selected from R19; R11 is carboxy, sulpho, sulphino, phosphono, -P(O)(ORc)(ORd), -P(O)(OH)(ORc), -P(O)(OH)(Rd) or -P(O)(ORc)(Rd) wherein Rc and Rd are independently selected from C1-6alkyl; or R11 is a group of formula (IB):
(IB) wherein:
Y is -N(RX)-, -N(Rx)C(O)-, -O-, and -S(O)a-; wherein a is 0-2 and Rx is hydrogen or C1- alkyl;
R12 is hydrogen or C1-4alkyl; R13 and R14 are independently selected from hydrogen, C1-6alkyl, carbocyclyl or heterocyclyl; wherein R13 and R14 may be independently optionally substituted by one or more substituents selected from R20;
R1S is carboxy, sulpho, sulphino, phosphono, -P(O)(ORe)(ORf), -P(O)(OH)(ORe), -P(O)(OH)(Re) or -P(O)(ORe)(Rf) wherein Re and Rf are independently selected from C1-6alkyl; or R15 is a group of formula (IC):
c) wherein:
R24 is selected from hydrogen or C1-4alkyl; R25 is selected from hydrogen, C1-4alkyl, carbocyclyl, heterocyclyl or R27; wherein said
C1- alkyl, carbocyclyl or heterocyclyl may be independently optionally substituted by one or more substituents selected from R28;
R26 is selected from carboxy, sulpho, sulphino, phosphono, tetrazolyl, -P(O)(ORg)(ORh), -P(O)(OH)(ORg), -P(O)(OH)(Rg) or -P(O)(ORg)(Rh) wherein Rg and Rh are independently selected from C1-6alkyl; p is 1-3; wherein the values of R13 maybe the same or different; q is 0-1; r is 0-3; wherein the values of R14 may be the same or different; m is 0-2; wherein the values of R10 may be the same or different; n is 1-3; wherein the values of R may be the same or different; z is 0-3; wherein the values of R may be the same or different; R16, R17 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1- alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1- alkyl)carbamoyl, N,N-(C1- alkyl) carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl and N,N-(C1-4alkyl)2sulphamoyl; wherein R16, R17 and R18 may be independently optionally substituted on carbon by one or more R ;
R19, R20, R27 and R28 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C - alkenyl, C2-4alkynyl, C1-4alkoxy, Cι-4alkanoyl, C1- alkanoyloxy, N-(C1- alkyl)amino, N,N-(C1-4alkyl)2amino, C1- alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, N,N-(C1- alkyl)2Sulphamoyl, carbocyclyl, heterocyclyl, sulpho, sulphino, amidino, (C1- alkyl)3silyl, phosphono, -P(O)(ORa)(ORb), -P(O)(OH)(ORa), -P(O)(OH)(Ra) or -P(O)(ORa)(Rb), wherein Ra and Rb are independently selected from C1-6alkyl; wherein R19 and R20 may be independently optionally substituted on carbon by one or more R22;
R21 and R22 are independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxy, methylamino, dimethylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, niethylthio, methylsulphinyl, mesyl, N-methylsulphamoyl and N,N-dimethylsulphamoyl; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
According to a further feature of the present invention there is provided a compound of formula (I):
(I) wherein:
One of R1 and R2 are selected from hydrogen or C1-6alkyl and the other is selected from C1-6alkyl;
Ry is selected from hydrogen, hydroxy, C1-6alkyl, C1-4alkoxy and C1-6alkanoyloxy;
Rz is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl and N,N-(C1-6alkyl)2sulphamoyl; v is 0-5; one of R4 and R5 is a group of formula (IA):
R3 and R6 and the other of R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1-4alkoxy, C1- alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, C1- alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl and N,N-(C1- alkyl)2sulphamoyl; wherein R3 and R6 and the other of R4 and R5 may be optionally substituted on carbon by one or more R16; X is -O-, -N(Ra)-, -S(O)b- or -CH(Ra)-; wherein Ra is hydrogen or C1-6alkyl and b is 0- 2;
Ring A is aryl or heteroaryl; wherein Ring A is optionally substituted by one or more substituents selected from R17; R7 is hydrogen, C1-4alkyl, carbocyclyl or heterocyclyl; wherein R7 is optionally substituted by one or more substituents selected from R18;
R8 is hydrogen or C1- alkyl;
R9 is hydrogen or C1-4alkyl;
R10 is hydrogen, C1-4alkyl, carbocyclyl or heterocyclyl; wherem R10 is optionally substituted by one or more substituents selected from R19;
R11 is carboxy, sulpho, sulphino, phosphono, -P(O)(ORc)(ORd), -P(O)(OH)(ORc), -P(O)(OH)(Rd) or -P(O)(ORc)(Rd) wherein Rc and Rd are independently selected from C1-6alkyl; or R11 is a group of formula (IB):
(IB) wherein:
Y is -N(RX , -N(Rx)C(O)-, -O-, and -S(O)a-; wherein a is 0-2 and Rx is hydrogen or C1-4alkyl;
R12 is hydrogen or C1-4alkyl; R13 and R14 are independently selected from hydrogen, C1-4alkyl, carbocyclyl or heterocyclyl; wherein R13 and R14 maybe independently optionally substituted by one or more substituents selected from R ;
R15 is carboxy, sulpho, sulphino, phosphono, -P(O)(ORe)(ORf), -P(O)(OH)(ORe), -P(O)(OH)(Re) or -P(O)(ORe)(Rf) wherem Re and Rf are independently selected from C1-6alkyl p is 1-3; wherem the values of R13 may be the same or different; q is 0-1; r is 0-3; wherein the values of R14 maybe the same or different; m is 0-2; wherem the values of R10 may be the same or different; n is 1-3; wherein the values of R7 may be the same or different; R16, R17 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2- alkenyl, C2-4alkynyl, C1-4alkoxy, C1- alkanoyl, C1- alkanoyloxy, N-(C1- alkyl)amino, N,N-(C1-4alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1- alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl and
N,N-(C1-4alkyl)2sulphamoyl; wherein may be independently optionally substituted on carbon by one or more R21;
R19 and R20 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino,
C1- alkanoylamino, N-(C1- alkyl)carbamoyl, N,N-(C1-4alkyl) carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1- alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl, N,N-(C1- alkyl)2sulphamoyl, carbocyclyl, heterocyclyl, sulpho, sulphino, amidino, phosphono, -P(O)(ORa)(ORb), -P(O)(OH)(ORa), -P(O)(OH)(Ra) or -P(O)(ORa)(Rb), wherein Ra and Rb are independently selected from C1-6alkyl; wherein R19 and R20 may be independently optionally substituted on carbon by one or more R22;
R21 and R22 are independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxy, methylamino, dimethylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, methylthio, methylsulphinyl, mesyl, N-methylsulphamoyl and N.N-dimethylsulphamoyl; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrag thereof. h this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C1-6alkyl" includes C1-4alkyl, propyl, isopropyl and t-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals, for example "phenylC1-6alkyl" would include phenylC1-6alkyl, benzyl,
1-phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo. Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
"Heteroaryl" is a totally unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Preferably "heteroaryl" refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Examples and suitable values of the term "heteroaryl" are thienyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranyl, indolyl, pyrimidyl, pyrazinyl, pyridazinyl, pyridyl and quinolyl. Preferably the term "heteroaryl" refers to thienyl or indolyl.
"Aryl" is a totally unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms. Preferably "aryl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "aryl" include phenyl or naphthyl. Particularly "aryl" is phenyl.
A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form the S-oxides. Preferably a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- or a ring sulphur atom may be optionally oxidised to form S-oxide(s). Examples and suitable values of the term "heterocyclyl" are thiazolidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2,5-dioxopyrrolidinyl, 2-benzoxazolinonyl, 1 , 1 -dioxotetrahydrothienyl, 2,4-dioxoimidazolidinyl, 2-oxo-l,3,4-(4-triazofinyι), 2-oxazolidinonyl, 5,6-dihydrouracilyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, 2,3-dihydrobenzofuranyl, benzothienyl, tetrahydropyranyl, piperidyl, l-oxo-l,3-dihydroisoindolyl, piperazinyl, thiomorpholino, 1,1-dioxothiomorpholino, tetrahydropyranyl, 1,3-dioxolanyl, homopiperazinyl, thienyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl, 1,3, 4- triazolyl, pyranyl, indolyl, pyrimidyl, thiazolyl, pyrazinyl, pyridazinyl, pyridyl, 4-pyridonyl, quinolyl and 1-isoquinolonyl.
A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-. Preferably "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. Particularly "carbocyclyl" is cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl or 1-oxoindanyl.
An example of "Ci-ealkanoyloxy" and "C1-4alkanoyloxy"is acetoxy. Examples of "C1-6alkoxycarbonyl" and "C1-4alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of "C1-6alkoxy" "C1-4alkoxy" include methoxy, ethoxy and propoxy. Examples of "C1-6alkanoylamino" and "Cι- alkanoylamino" include formamido, acetamido and propionylamino. Examples of "Cι-6alkylS(O)a wherein a is 0 to 2" and "C1- alkylS(O)a wherein a is 0 to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C1-6alkanoyl" and "C1- alkanoyl" include propionyl and acetyl. Examples of "N-(C1-6alkyl)amino" and "N-(C1-4alkyl)amino" include methylamino and ethylamino. Examples of "N,N-(C1-6alkyl)2amino" and "N,N-(C1-4alkyl)2amino" include di-N-methylamino, di-(N-ethyl)amino and
N-ethyl-N-methylamino. Examples of "C2-6alkenyl" and "C2- alkenyl"are vinyl, allyl and 1-propenyl. Examples of "C2-6alkynyl" and "C2-4alkynyl" are ethynyl, 1-ρropynyl and 2-propynyl. Examples of "N-(Cι-6alkyl)sulphamoyι" and "N-(C1-4alkyl)sulphamoyl" are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of "N-(C1-6alkyl)2sulphamoyl" and "N-(Cι-4alkyl)2sulphamoyl" are N,N-(dimethyl)sulphamoyl and
N-(methyl)-N-(ethyl)sulphamoyl. Examples of "N-(C1-6alkyl)carbamoyr' and "N-(C1- alkyl)carbamoyl" are metl ylaminocarbonyl and ethylaminocarbonyl. Examples of "N,N-(C1-6alkyl)2carbamoyl" and "N,N-(C1-4alkyl)2carbamoyl" are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "(Cι-4alkyl)3silyl," include trimethylsilyl and methyldiethylsilyl.
A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric, acetate or maleic acid, h addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
The compounds of the fonnula (I) maybe administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I). examples of pro-drugs include in vivo hydrolysable esters and in vivo hydrolysable amides of a compound of the formula (I).
An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C1-6alkoxymethyl esters for example methoxymethyl, C1-6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3-8cycloalkoxycarbonyloxyC1-6alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl; and C1-6alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and maybe formed at any carboxy group in the compounds of this invention.
An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring. A suitable value for an in vivo hydrolysable amide of a compound of the formula (I) containing a carboxy group is, for example, aN-C1-6alkyl or N,N-di-C1-6alkyl amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethyl amide.
Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess IBAT inhibitory activity.
The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess IBAT inhibitory activity.
It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess IBAT inhibitory activity.
Particular values are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter. R1 and R2 are C1-4alkyl.
R1 and R2 are butyl. One of R1 and R2 is ethyl and the other is butyl.
1 1
One of R and R is ethyl and the other is butyl or R and R are both butyl. v is 0 or 1. v is 0.
Rz is C1-4alkyl.
Ry is hydrogen.
Ry is hydrogen or hydroxy.
R3 and R6 are hydrogen. R4 is methylthio.
R4 is hydrogen.
R4 is hydrogen, halo or C1-4alkylS(O)a wherein a is 0.
R4 is hydrogen, bromo or methylthio.
R5 is a group of formula (IA) (as depicted above) wherein: X is -O-; n is 1;
R7 is hydrogen; R8 is hydrogen;
R9 is hydrogen; m is 0; and
R11 is carboxy. R5 is N-((R)-α-carboxybenzyl)carbamoylmethoxy.
R5 is a group of formula (IA) (as depicted above); wherein
X is -O-;
Ring A is aryl; wherein Ring A is optionally substituted by one or more substituents selected from R17; R7 is hydrogen;
R8 is hydrogen;
R9 is hydrogen;
R11 is carboxy; or R11 is a group of formula (IB) (as depicted above); wherein:
R12 is hydrogen; R13 is hydrogen;
R15 is carboxy or sulpho; p is 1 or 2; q is 0; r is O; m is 0; n is 1; and
R17 is hydroxy.
R5 is a group of formula (IA) (as depicted above); wherein
X is -O-; Ring A is phenyl or 4-hydroxyphenyl;
R7 is hydrogen;
R8 is hydrogen;
R9 is hydrogen;
R11 is carboxy; or R11 is a group of formula (IB) (as depicted above); wherein: R12 is hydrogen;
R13 is hydrogen;
R15 is carboxy or sulpho; p is 1 or 2; q is 0; r is 0; m is 0; and n is 1 ;
R5 is N-((R)-α-carboxybenzyl)carbamoylmethoxy; N-{(R)-α-[N- (carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy; orN-{(R)-α-[N-(2- sulphoethyl)carbamoyl] -4-hydroxybenzyl} carbamoylmethoxy.
Therefore in one aspect of the invention there is provided a compound of formula (I) (as depicted above)
R1 and R2 are C1-4alkyl; v is O;
Ry is hydrogen or hydroxy;
R3 and R6 are hydrogen; R4 is hydrogen, halo or C1-4alkylS(O)a wherein a is 0;
R5 is a group of formula (I ) (as depicted above); wherein
X is -O-;
Ring A is aryl; wherein Ring A is optionally substituted by one or more substituents
17 selected from R ; R7 is hydrogen;
R8 is hydrogen;
R9 is hydrogen;
R11 is carboxy; or R11 is a group of formula (IB) (as depicted above); wherein:
R12 is hydrogen; R13 is hydrogen;
R15 is carboxy or sulpho; p is 1 or 2; q is 0; r is O; m is 0; n is 1; and
R17 is hydroxy; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Therefore in one aspect of the invention there is provided a compound of formula (I) (as depicted above)
One of R1 and R2 is ethyl and the other is butyl; v is O;
Ry is hydrogen or hydroxy;
R3 and R6 are hydrogen;
R4 is hydrogen, bromo or methylthio;
R5 is N-((R)-α-carboxybenzyl)carbamoylmethoxy; N-{(R)-α-[N- (carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy; or N-{(R)-α-[N-(2- sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In another aspect of the invention, preferred compounds of the invention are any one of the examples or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Preferred aspects of the invention are those which relate to the compound of formula (I) or a pharmaceutically acceptable salt thereof.
Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of: Process 1): oxidising a benzothiazepine of formula (II):
(Rz)v
(π);
Process 2): for compounds of formula (I) wherein X is -O-,-ΝRa or -S-; reacting a compound of formula (Ilia) or (Illb): with a compound of formula (IV):
(IV) wherein L is a displaceable group;
Process 3): reacting an acid of formula (Va) or (Vb):
(Va) (Vb) or an activated derivative thereof; with an amine of formula (VI):
(VI); Process 4): for compounds of formula (I) wherein R11 is a group of formula (IB); reacting a compound of formula (I) wherein R11 is carboxy with an amine of formula (VII):
(VII)
Process 5): for compounds of formula (I) wherein R11 is a group of formula (IB) and R15 is a group of formula (IC) reacting a compound of formula (I) wherein R15 is carboxy with an amine of formula (VIII):
(VIII)
Process 6) for compounds of formula (I) wherein one of R4 and R5 are independently selected from -ealkylthio optionally substituted on carbon by one reacting a compound of formula (IXa) or (IXb):
(TXa) (IXb) wherein L is a displaceable group; with a thiol of formula (X):
Rm-H
(X) wherein Rm is C1-6alkylthio optionally substituted on carbon by one or more R , 11D6;. Process 7): for compounds of formula (I) wherein R11 is carboxy; deprotecting a compound of formula (XIa):
(XIa) or (Xlb):
(Xlb) wherein Rx together with the -OC(O)- group to which it is attached forms an ester; Process 8): for compounds of formula (I) wherein R11 is a group of formula (IB) and R15 is carboxy; deprotecting a compound of formula (Xlla):
(Xlla) or (Xllb):
(Xllb) wherein RX together with the -OC(O)- group to which it is attached forms an ester; Process 9): for compounds of formula (I) wherein R11 is a group of formula (IB) and Y is -N(Rx)C(O)-; reacting an acid of formula (Xllla):
(Xllla) or (Xlllb):
(Xlllb) or an activated derivative thereof; with an amine of formula (XIV):
(XIV) or Process 10): for compounds of formula (I) wherein R11 is a group of formula (IB), R15 is a group of formula (IC) and R26 is carboxy; deprotecting a compound of formula (XVa):
(XVa) or (XVb):
(XVb) wherein Rx together with the -OC(O)- group to which it is attached forms an ester; and thereafter if necessary or desirable: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug. L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulρhonyloxy group.
Rx together with the -OC(O)- group to which it is attached forms an ester. Preferably Rx is methyl or ethyl. More preferably Rx is methyl. In another aspect of the invention Rx is C1- alkyl or phenylC1-6alkyl, preferably C1-4alkyl or benzyl, more preferably t-butyl, methyl, ethyl or benzyl.
Specific reaction conditions for the above reactions are as follows. Process 1): Benzothiazepines of formula (II) may be oxidised under standard sulphur oxidation conditions; for example using hydrogen peroxide and trifluoroacetic acid at a temperature in the range of 0°C to reflux, preferably at or near room temperature.
Compounds of formula (II) may be prepared according to Scheme I:
i) Diborane, THF ii) (Optionally) adding Ry group
Scheme 1 Compounds of formula (Ila), (lib) and (Ilf) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process 2): Compounds of formula (Ilia) or (Illb) maybe reacted with compounds of formula (IV) in the presence of a base for example an inorganic base such as sodium carbonate, or an organic base such as Hunigs base, in the presence of a suitable solvent such as acetonitrile, dichloromethane or tetrahydrofuran at a temperature in the range of 0°C to reflux, preferably at or near reflux.
Compounds of formula (Ilia) or (Illb) may be prepared in a similar manner to compounds of formula (II) but wherem R4 or R5 is -OH, -NH(Ra) or -SH (optionally for -SO- and -SO2- followed by the oxidation step of Process 1). Compounds of formula (Ilia) or (Illb) wherein X is -O- or -S- may also be prepared by the procedures disclosed in WO 9605188.
Compounds of formula (IV) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process 3) and Process 4) and Process 5) and Process 9): Acids and amines may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-«/ y/-pyridines such as 2,6-lutidine or 2,6-di-tert-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
Compounds of formula (Va) or (Vb) wherein X=-O-,-NRa,-S- may be prepared according to Scheme 2: (Vc)
(IXa) — *- (Va)
NaCO3
MeCN
(Vc) (IXb) *~ (Vb)
NaCO3
MeCN Scheme 2 Wherein L in (IXa) and (IXb) is a displaceable group e.g. bromo, chloro, fluoro, mesyl or tosyl and wherein X is -O-,-S-, NRa (optionally for -SO- and -SO2- followed by the oxidation step of Process 1).
Compounds of formula (Va) and (Vb) where X is -SO- or -SO2- maybe prepared by oxidising the resulting compounds of formula (Va) and (Vb) from Scheme 2 where X is -S-.
Compounds of formula (Va) or (Vb) wherein X is -CH2-, and n is 1, may be prepared according to Scheme 3.
Scheme 3
The skilled person will appreciate that the above reaction scheme may be manipulated to prepare compounds of formula (Va) or (Vb) where n is 2 or 3.
Compounds of formula (Xllla) or (Xlllb) maybe prepared by manipulations known to the skilled person of the processes described herein.
Compounds of formula (Vc), (VI), (VII), (VIII) and (XIV) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Process 6): Compounds of formula (IXa) and (IXb) may be reacted with thiols of formula (X) in the presence of base, for example an inorganic base such as sodium carbonate or an organic base such as Hunigs base, in the presence of a suitable solvent such as DMF or THF at a temperature in the range of 0°C to reflux.
Compounds of formula (IXa) and (IXb) may be prepared by any of the procedures above for the preparation of compounds of formula (I), but wherein one of R4 and R5 is L. Compounds of formula (X) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process 7) and Process 8) and Process 10): Esters of formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) and (XVb) may be deprotected under standard conditions such as those described below, for Example they may be deprotected with sodium hydroxide in methanol at room temperature.
Esters of formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) and (XVb) may be prepared by any of the procedures above for the preparation of compounds of formula (I), but wherein R11 or R15 or R26 is an ester. It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1999). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein. A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
As stated hereinbefore the compounds defined in the present invention possess IBAT inhibitory activity. These properties may be assessed, for example, using an in vitro test assay for studying the effect on bile acid uptake in IBAT-transfected cells (Smith L., Price- Jones M. J., Hugnes K. T. and Jones N. R. A.; J Biomolecular Screening, 3, 227-230) or in vivo by studying the effect on radiolabelled bile acid absorption in mice/rats (Lewis M. C, Brieaddy L. E. and Root C, J., J Lip Res 1995, 36, 1098-1105). According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
In general the above compositions may be prepared in a conventional manner using conventional excipients. The compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.02-100 mg/kg, preferably 0.02 -50 mg kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg, particularly 0.1-10 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.
We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are effective IBAT inhibitors, and accordingly have value in the treatment of disease states associated with hyperlipidaemic conditions. Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use as a medicament.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore, in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore, in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the foπnula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man. Herein, where "the production of an IBAT inhibitory effect" or "producing an IBAT inhibitory effect" is referred to particularly this refers to the treatment of hyperlipidaemic conditions, hi another aspect, "the production of an IBAT inhibitory effect" or "producing an IBAT inhibitory effecf'refers to the treatment of dyslipidemic conditions and disorders such as hyperlipidaemia, hypertrigliceridemia, hyperbetalipoproteinemia (high LDL), hyperprebetalipoproteinemia (high NLDL), hyperchylomicronemia, hypolipoproteinemia, hypercholesterolemia, hyperlipoproteinemia and hypoalphalipoproteinemia (low HDL). In another aspect "the production of an IBAT inhibitory effect" or "producing an IBAT inhibitory effect" refers to the treatment of different clinical conditions such as atherosclerosis, arteriosclerosis, arrhythmia, hyper-thrombotic conditions, vascular dysfunction, endothehal dysfunction, heart failure, coronary heart diseases, cardiovascular diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, inflammation of cardiovascular tissues such as heart, valves, vasculature, arteries and veins, aneurisms, stenosis, restenosis, vascular plaques, vascular fatty streaks, leukocytes, monocytes and/or macrophage infiltration, intimal thickening, medial thinning, infectious and surgical trauma and vascular thrombosis, stroke and transient ischaemic attacks. In another aspect "the production of an IBAT inl ibitory effect" or "producing an IBAT inhibitory effect" refers to the treatment of atherosclerosis, coronary heart diseases, myocardial infarction, angina pectoris, peripheral vascular diseases, stroke and transient ischaemic attacks in a warm-blooded animal, such as man.
According to a further feature of this aspect of the invention there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
According to a further feature of this aspect of the invention there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment wliich comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
The size of the dose required for the therapeutic or prophylactic treatment will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 0.1-50 mg/kg preferably 0.1-10 mg/kg is envisaged.
The IBAT inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore and an additional IBAT inhibitory substance as defined hereinbefore and an additional hypolipidaemic agent for the conjoint treatment of hyperlipidaemia.
In another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in association with an HMG Co-A reductase inhibitor, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable HMG Co-A reductase inhibitors, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are statins well known in the art. Particular statins are fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, dalvastatin, mevastatin and (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl)amino]pyrimidin-5-yl](3R,5S)-3,5- dihydroxyhept-6-enoic acid (rosuvastatin), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A further particular statin is (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl)ammo]pyrimidin-5-yl](3R,5S)-3,5- dihydroxyhept-6-enoic acid, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is rosuvastatin calcium salt.
In an additional aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof may be administered in association with an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and/or a bile acid binder thereby avoiding a possible risk of excess of bile acids in colon caused by the inhibition of the ileal bile acid transport system. An excess of bile acids in the visceral contents may cause diarrhoea. Thus, the present invention also provides a treatment of a possible side effect such as diarrhoea in patients during therapy comprising the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
An HMG CoA-reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof will by its action decrease the endogenous cholesterol available for the bile acid synthesis and have an additive effect in combination with the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof on lipid lowering.
Suitable bile acid binders for such a combination therapy are resins, such as cholestyramine and cholestipol. One advantage is that the dose of bile acid binder might be kept lower than the therapeutic dose for treatment of cholesterolaemia in single treatment comprising solely a bile acid binder. By a low dose of bile acid binder any possible side effects caused by poor tolerance of the patient to the therapeutic dose could also be avoided. Therefore in an additional feature of the invention, there is provided a method for producing an JB AT inliibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Therefore in an additional feature of the invention, there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with a bile acid binder.
Therefore in an additional feature of the invention, there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in simultaneous, sequential or separate administration with a bile acid binder.
Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a bile acid binder.
Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in simultaneous, sequential or separate administration with a bile acid binder.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder, in association with a pharmaceutically acceptable diluent or carrier. According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder in association with a pharmaceutically acceptable diluent or carrier.
According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder. According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof and a bile acid binder.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form; b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and c) container means for containing said first and second dosage forms.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form; b) a bile acid binder; in a second unit dosage form; and c) container means for containing said first and second dosage forms.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form; b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; c) a bile acid binder; in a third unit dosage form; and d) container means for containing said first, second and third dosage forms.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form; b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and c) container means for containing said first and second dosage forms.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form; b) a bile acid binder, in a second unit dosage form; and c) container means for containing said first and second dosage forms.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form; b) an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage fonn; and c) a bile acid binder; in a third unit dosage form; and d) container means for containing said first, second and third dosage forms. According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man. According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, a bile acid binder, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.
According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.
According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of a bile acid binder, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment. According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable excipient, with the simultaneous, sequential or separate administration of an effective amount of a bile acid binder, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.
According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from:
> a CETP (cholesteryl ester transfer protein) inhibitor, for example those referenced and described in WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference; > a cholesterol absorption antagonist for example azetidinones such as SCH 58235 and those described in US 5,767,115 which are incorporated herein by reference;
> a MTP (microsomal transfer protein) inhibitor for example those described in Science, 282, 751-54, 1998 which are incorporated herein by reference;
> a fibric acid derivative; for example clofibrate, gemfibrozil, fenofibrate, ciprofibrate and bezafibrate;
> a nicotinic acid derivative, for example, nicotinic acid (niacin), acipimox and niceritrol;
> a phytosterol compound for example stanols;
> probucol; > an anti-obesity compound for example orlistat (EP 129,748) and sibutramine (GB
2,184,122 and US 4,929,629);
> an antihypertensive compound for example an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha andrenergic blocker, a beta andrenergic blocker, a mixed alpha beta andrenergic blocker, an andrenergic stimulant, calcium channel blocker, a diuretic or a vasodilator; insulin;
> sulphonylureas including glibenclamide, tolbutamide; > metformin; and/or
> acarbose; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment. Particular ACE inhibitors or pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof, including active metabolites, which can be used in combination with a compound of formula (I) include but are not limited to, the following compounds: alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril- glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrocl loride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril and zofenoprilat. Preferred ACE inhibitors for use in the present invention are ramipril, ramiprilat, lisinopril, enalapril and enalaprilat. More preferred ACE inhibitors for uses in the present invention are ramipril and ramiprilat.
Preferred angiotensin JJ antagonists, pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof for use in combination with a compound of formula (I) include, but are not limited to, compounds: candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan and eprosartan. Particularly preferred angiotensin IT antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil. fri another aspect of the invention, the compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, maybe administered in association with a PPAR alpha and/or gamma agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO 98/57941, WO 01/40170, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all incorporated herein by reference. Particularly a PPAR alpha and/or gamma agonist refers to WY-14643, clofibrate, fenofibrate, bezafibrate, GW 9578, troglitazone, pioglitazone, rosiglitazone, eglitazone, proglitazone, BRL-49634, KRP-297, JTT-501, SB 213068, GW 1929, GW 7845, GW 0207, L-796449, L-165041, NN622/Ragaglitazar, BMS 298585and GW 2433. Particularly a PPAR alpha and/or gamma agonist refers to (S)-2-ethoxy-3-[4-(2- {4-methanesulphonyloxyphenyl} ethoxy)phenyl] propanoic acid and pharmaceutically acceptable salts thereof.
Therefore in an additional feature of the invention, there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.
According to a further aspect of the present invention there is provided a kit comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form; b) a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and c) container means for containing said first and second dosage forms. According to a further aspect of the present invention there is provided a kit comprising: a) a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form; b) a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and c) container means for containing said first and second dosage forms.
According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man. According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man. According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.
In addition to their use in therapeutic medicine, the compounds of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of IBAT in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
Many of the intermediates described herein are novel and are thus provided as a further feature of the invention. For Example compounds of formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) and (XVb) show IBAT inhibitory activity when tested in the above referenced in vitro test assay and are thus claimed as a further feature of the invention.
Thus in a further feature of the invention, there is provided a compound of formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
Therefore according to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
According to an additional aspect of the present invention there is provided a compound of the formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.
Thus according to this aspect of the invention there is provided a compound of the foπnula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as defined hereinbefore for use as a medicament.
According to another feature of the invention there is provided the use of a compound of the formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof as defined hereinbefore in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.
According to another feature of the invention there is provided the use of a compound of the formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof as defined hereinbefore in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.
According to a further feature of this aspect of the invention there is provided a method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment wliich comprises administering to said animal an effective amount of a compound of formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
According to a further feature of this aspect of the invention there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (XIa), (Xlb), (Xlla), (Xllb), (XVa) or (XVb), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply. Examples
The invention will now be illustrated in the following non limiting examples, in which standard techniques known to the skilled chemist and techniques analogous to those described in these examples may be used where appropriate, and in which, unless otherwise stated: (i) evaporations were carried out by rotary evaporation in vacuo and work up procedures were carried out after removal of residual solids such as drying agents by filtration; (ii) all reactions were carried out under an inert atmosphere at ambient temperature, typically in the range 18-25°C, with solvents of HPLC grade under anhydrous conditions, unless otherwise stated;
(iii) column chromatography (by the flash procedure) was performed on Silica gel 40-63 μm (Merck);
(iv) yields are given for illustration only and are not necessarily the maximum attainable; (v) the structures of the end products of the formula (I) were generally confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; magnetic resonance chemical shift values were measured in deuterated CD3OD (unless otherwise stated) on the delta scale (ppm downfield from tetramethylsilane); proton data is quoted unless otherwise stated; spectra were recorded on a Narian Mercury-300 MHz, Narian Unity pIus-400 MHz, Narian Unity plus-600 MHz or on Narian Inova-500 MHz spectrometer; and peak multiplicities are shown as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; tt, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad; LCMS were recorded on a Waters ZMD, LC column xTerra MS C8(Waters), detection with a HP 1100 MS-detector diode array equipped; mass spectra (MS) (loop) were recorded on NG Platform II (Fisons Instruments) with a HP- 1100 MS-detector diode array equipped; unless otherwise stated the mass ion quoted is (MH1"); (vi) unless further details are specified in the text, analytical high performance liquid chromatography (HPLC) was performed on Prep LC 2000 (Waters), Kromasil C8, 7μm, (Akzo Νobel); MeCΝ and de-ionised water 100 mM ammonium acetate as mobile phases, with suitable composition;
(vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), HPLC, infra-red (IR), MS or ΝMR analysis; (viii) where solutions were dried sodium sulphate was the drying agent;
(ix) where an "ISOLUTE" column is referred to, this means a column containing 2g of silica, the silica being contained in a 6 ml disposable syringe and supported by a porous disc of 54A pore size, obtained from International Sorbent Technology under the name "ISOLUTE"; "ISOLUTE" is a registered trade mark; (x) the following abbreviations may be used hereinbefore or hereinafter:- DCM dichloromethane;
DMF Ν,Ν-dimethylformamide; TFA trifluoroacetic acid;
TBTU o-Benzotriazol- 1 -yl-N,N,N^N'-teframethyluronium tetrafluoroborate;
EtOAc ethyl acetate; and
MeCN acetonitrile.
Example 1
1.1 -Dioxo-3(RV3-butyl-3-ethyl-5-(R -5-phenyl-8-rN-((R -α-carboxybenzvn carbamoylmethoxyl-2,3,4,5-tetrahydro- 4-benzothiazepine; and 1.1 -Dioxo-3(S -3-butyl-3-ethyl-5-(S -5-rjhenyl-8-rN-((RVα-carboxybenzvn carbamoylmethoxy]-2,3,4,5-tetrahvdro-l,4-benzothiazepine
(+-)-trans- 1 , 1 -Dioxo-3 -butyl-3 -ethyl-5 -phenyl- 8-(carboxymethoxy)-2,3 ,4,5 -tetrahydro- 1,4-benzothiazepine (Method 1; 13 mg, 0.03 mmol) methyl (2R)-amino(phenyl)acetate (7.5 mg, 0.037 mmol) and diisopropylethylamine (24 mg, 0.19 mmol) were dissolved in DCM (1.5 ml). The mixture was stirred for 10 min and then TBTU (12 mg, 0.037 mmol) was added and the reaction mixture was stirred for 30 min. The solvent was removed under reduced pressure. The residue was dissolved in ethanol (2 ml) and sodium hydroxide (2 mg) was added. The mixture was stirred for 30 min and the solvent was evaporated. The residue was purified by chromatography (DCM : EtOAc : AcOH, 100:10:3) giving the title compound (5.5 mg, 32%). M/z: 565.3 (MH+), 563.2 (M").
Example 2 l.l-Dioxo-3(R -3-butyl-3-ethyl-5-(R)-5-phenyl-8-(N-((R - -rN-rcarboxymethvncarbamoyll benzyl! carbamoylmethoxy)-2,3 A5-tetrahydro- 1 ,4-benzothiazepine; and Ll-Dioxo-3(S -3-butyl-3-ethyl-5-(SV5-phenyl-8-rN-(rRVa-rN-rcarboxymethvncarbamoyll benzyl} carbamoylmethoxyV2.3 ,4,5-tetrahvdro- 1 ,4-benzothiazepine
An equal mixture of l,l-dioxo-3-(R)-3-butyl-3-ethyl-5-(R)-5-phenyl-8-(N-{(R)-α-[N- (t-butoxycarbonylmethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro- 1 ,4- benzothiazepine and 1 , 1 -dioxo-3-(S)-3-butyl-3-ethyl-5-(S)-5-phenyl-8-(N- {(R)- -[N-(t- butoxycarbonylmethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3 ,4,5-tetrahydro- 1 ,4- benzothiazepine (Method 2; 27 mg, 0.040 mmol) were dissolved in 2 ml DCM.
Trifluoroacetic acid (0.2 ml, 2.60 mmol) was added and the mixture was stirred overnight at ambient temperature. The reaction mixture was concentrated under reduced pressure and then purified with preparative HPLC using an MeCN/ammonium acetate buffer gradient (5/95 to 60/40) as eluent. The MeCN was evaporated and lyophilisation of the remaining solution resulted in the title products in 69% yield (16 mg). NMR (400 MHz, MeOD): 0.81 (t, 3H), 0.89 (t, 3H), 1.11-1.35 (m, 4H), 1.41-1.50 (m, IH), 1.52-1.62 (m, IH), 1.74-1.84 (m, IH), 2.17-2.28 (m, IH), 3.34 (ABq, 2H), 3.87 (ABq, 2H), 4.63-4.66 (m, 2H), 5.61 (s, IH), 6.00 (s, IH), 6.59-6.64 (m, IH), 6.95-7.01 (m, IH), 7.27-7.44 (m, 10H), 7.64-7.67 (m, IH); m z: 622 (M+l).
Example 3 3 ,5-trans- 1.1 -Dioxo-3-ethyl-3-butyl-5-phenyl-7-bromo-8-rN- {(RVα-rN-
(carboxymethyl carbamoyl]benzyllcarbamoyhnethoxy -2,3,4,5-tetrahvdro- 4- benzothiazepine
3,5-trαrø-l,l-Dioxo-3-ethyl-3-butyl-5-phenyl-7-bromo-8-(carboxymethoxy)-2,3,4,5- tetrahydro-l,4-benzothiazepine (Method 5; 50 mg, 0.10 mmol) was dissolved in DCM (3 ml). Lutidine (0.023 ml, 0.198 mmol), TBTU (38 mg, 0.118 mmol) and (R)-α-[N-(t- butoxycarbonyhnethyl)carbamoyl]benzylamine (Method 4; 44 mg, 0.167 mmol) were added successively. The mixture was stirred over night at ambient temperature. The solution was concentrated to 1 ml and TFA (1.3 ml) was added. The mixture was concentrated after 1.5h and the residue was purified using preparative HPLC. A gradient from 40% to 60% of MeCΝ in 0.1 M ammonium acetate buffer was used as eluent. Lyophilisation yielded 39 mg (57%). ΝMR (400 MHz) 0.75 (t, 3H), 0.95 (t, 3H), 1.2-1.4 (m, 6H), 1.75-1.9 (m, IH), 2.2-2.4 (m, IH), 3.35 (dd, 2H), 3.85 (dd, 2H), 4.7-4.8 (m, 2H), 5.6 (s, IH), 6.0 (d, IH), 6.8 (d, IH), 7.25- 7.5 (m, 10H), 7.6 (d, IH); m/z: 700 (M) and 702 (M+2)2+.
Example 4
3,5-trαrø- l-Dioxo-3-(SV3-ethyl-3-butyl-4-hvdroχy-5-(SV5-phenyl-7-bromo-8-(N-{(RVα- [N-(carboxymethyl carbarnoyl"lbenzyl} carbamoylmethoxy)-2,3 ,4,5-tetrahvdro- 1.4- benzothiazepine
3,5-trαw^- l-Dioxo-3-rRV3-ethyl-3-butyl-4-hvdroxy-5-(RV5-ϋhenyl-7-bromo-8-(N-l(RVα- [N-(carboxyιnethvDcarbamoyllbenzyl>carbamoylmethoxyV2.3,4,5-tetrahvdro-1.4- benzothiazepine 3,5-t «-?-l,l-Dioxo-3-ethyl-3-butyl-5-phenyl-7-bromo-8-(N-{(R)-α-[N- (carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-l,4- benzothiazepine (Example 3; 14 mg, 0.02 mmol) was dissolved in 2 ml DCM. m- Chloroperoxybenzoic acid (5.5 mg, 0.022 mmol) was added and the mixture was stirred for 30 5 min. The diastereomers of the title compound were separated using preparative HPLC on a C8 column. A gradient from 30% to 60% of MeCΝ in 0.1 M ammonium acetate buffer was used as eluent. The two compounds were lyophilized and the first eluting diastereomer was obtained in 5.4 mg and the second in 4.9 mg. M/z: 716 (M) and 718 (M+2)2+. ΝMR (400 MHz) (diastereomer 1) 0.86 (t, 3H), 0.95 (t, 3H), 1.1-1.4 (m, 3H), 1.4-1.55 (m, 2H), 1.68-1.8 0 (m, IH), 2.0-2.2 (m, 2H), 3.4 (dd, 2H), 3.88 (Abq, 2H), 4.76 (Abq, 2H), 5.6 (s, IH), 6.45 (s, IH), 6.88 (s, IH), 7.25-7.50 (m, 10H), 7.56 (s, IH). ΝMR (diastereomer 2) (400 MHz) 0.87 (t, 3H), 0.95 (t, 3H), 1.1-1.4 (m, 3H), 1.4-1.55 (m, 2H), 1.68-1.8 (m, IH), 2.0-2.22 (m, 2H), 3.4 (dd, 2H), 3.82 (Abq, 2H), 4.76 (Abq, 2H), 5.6 (s, IH), 6.46 (s, IH), 6.88 (s, IH), 7.25-7.50 (m, 10H), 7.57 (s, IH).
[5
Example 5
3,5-tr n-?- l-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methyltlήo-8-(N-((RVα-|'N- (carboxymethvPcarbamoyllbenzyl) carbamoyhnethoxy -2,3 ,4,5-tetralιydro- 1 A- benzothiazepine
20 3,5-trans- 1 , 1 -Dioxo-3-ethyl-3-butyl-5 -phenyl-7-methylthio-8-(carboxymethoxy)-
2,3,4,5-tetrahydro-l,4-benzothiazepine (Method 6; 50 mg, 0.105 mmol) was dissolved in DCM (2 ml). 2,6-Lutidine (0.025 ml, 0.215 mmol), TBTU (45 mg, 0.140 mmol) and (R)-α- [N-(t-butoxycarbonylmethyl)carbamoyl]benzylamine (Method 4; 43 mg, 0.163 mmol) were added successively. The mixture was stirred for 2 hours at ambient temperature. The solution 5 was concentrated and the intermediate ester was purified by cliromatography on silica using DCM/EtOAc (9/1) as eluent. The solvent was evaporated to yield 45 mg (60%). M/z: 724. The ester was dissolved in 3 ml DCM and hydrolysed by addition of TFA (1 ml). After 2 hours the mixture was concentrated and purified using preparative HPLC. A gradient of MeCΝ from 40% to 60% in 0.1 M ammonium acetate buffer was used as eluent. 0 Lyophilisation yielded 33 mg (80%). ΝMR (400 MHz): 0.75-0.85 (m, 3H), 0.85-0.95 (m, 3H), 1.1-1.65 (m, 6H), 1.75-1.9 (m, IH), 2.0 (s, 3H), 2.2-2.4 (m, IH), 3.1-3.55 (m, 2H), 3.85 (ABq, 2H), 4.6-4.8 (m, 2H), 5.6 (s, IH), 5.98-6.03 (m, IH), 6.4 (s, IH), 7.25-7.56 (m, 11H); m/z: 668.
Example 6 3,5-trα^- l-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-((RVα-rN-r2- sulphoethyl)carbamoyll-4-hvdroxybenzyl>carbamoylmethoxy)-2,3,4,5-tetrahvdro-L4- benzothiazepine ammonia salt
3,5-t7- rø-l,l-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(carboxymethoxy)- 2,3,4,5-tetrahydro-l,4-benzothiazepine (Method 6; 33 mg, 0.070 mmol) was dissolved in DMF (3 ml) . 2- { [(2R)-2- Amino-2-(4-hydroxyphenyl)ethanoyl] amino } ethanesulphonic acid (Method 8; 23 mg, 0.084 mmol), N-methylmorpholine (0.025 ml, 0.227 mmol) and TBTU (27 mg, 0.084 mmol) were added successively and the mixture was stirred overnight. The solvent was removed and the crude product was purified using preparative HPLC. A gradient from 40% to 70% of MeCΝ in 0.1 M ammonium acetate buffer was used as eluent. Lyophilisation yielded 42 mg (80%) of the ammonium salt. ΝMR(400 MHz): 0.73-0.85 (m, 3H), 0.85-0.98 (m, 3H), 1.1-1.7 (m, 6H), 1.75-1.9 (m, IH), 2.0 (s, 3H), 2.15-2.4 (m, IH), 2.85-3.0 (m, 2H), 3.1-3.55 (m, 2H), 3.5-3.65 (m, 2H), 4.6-4.8 (m, 2H), 5.35-5.39 (m, IH), 5.98-6.05 (m, IH), 6.4 (s, IH), 6.75 (d, 2H), 7.15-7.5 (m, 8H); m/z: 734.
Example 7
Ll-Dioxo-3-rS -3-ethyl-3-butyl-5-('SV5-phenyl-7-methylthio-8-rN-((R)- -rN- (carboxymethyl carbamoyl]benzyl|carbamoylmethoxy -2,3,4,5-tetrahydro-L4- benzothiazepine diethylamine salt l.l-Dioxo-3-('R -3-ethyl-3-butyl-5-(RV5-phenyl-7-methylthio-8-(N-{(R -α-rN- (carboxymethyl carbamovι"|benzyl} carbamoylmethoxy)-2,3 ,4,5-tetrahydro- 1 A- benzothiazepine diethylamine salt
The diasteromeric mixture of 3,5-tr π_?-l,l-dioxo-3-ethyl-3-butyl-5-phenyl-7- methylthio-8-(N-{(R)- -[N-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5- tetrahydro-l,4-benzothiazepine (Example 5; 17 mg, 0.026 mmol) was separated by chiral chromatography on a Cliirobiotic V chiral stationary phase. Two columns (250 x 20 mm) in series were used. A mobile phase consisting of 80% MeOH in water with 0.1% Et3Ν and 0.1% HO Ac was used as eluent. The first eluting diastereomer was collected in a 50 ml fraction and the solvent was removed under reduce pressure. Et3N remained according to NMR-analysis and the diastereomer was purified by chromatography over 0.5g SiO2 using DCM MeOH (9/1) as eluent. The solvent was removed and the product was dissolved in water and some MeCN. Lyophilisation yielded a white solid, which was dissolved in MeOH and filtered. A second lyophilisation yielded the diastereomer as the Et3N salt in 1 mg (4%). M/z: 668. NMR (H.OAc-d4) was consistent with Example 5. The e.e. was determined as 99%. The second eluting diastereomer was collected in a 200 ml fraction and the solvent was removed under reduced pressure. The residue was purified using preparative HPLC on a C8 column. A gradient from 35% to 50% MeCN in 0.1 M ammonium acetate was used as eluent. Lyophilisation yielded the diastereomer as the Et N salt in 3 mg (17 mg). M/z: 668. The e.e. was determined as 97%.
Preparation of Starting Materials
The starting materials for the Examples above are either commercially available or are readily prepared by standard Methods from known materials. For Example, the following reactions are an illustration, but not a limitation, of some of the starting materials used in the above reactions.
Method 1 (+-)-frans-lΛ-Dioxo-3-butyl-3-ethyl-5-phenyl-8-(carboxymethoxy)-2,3,4,5-tetrahvdro-l,4- benzothiazepine
1 , 1 -Dioxo-3 -butyl-3-ethyl-5-phenyl-8-hydroxy-2,3 ,4,5-tetrahydro- 1 ,4-benzothiazepine (prepared according to WO/9605188; 83 mg, 0,22 mmol), ethyl bromoacetate (55 mg, 0.33 mmol) and sodium carbonate (70 mg, 0.66 mmol) in acetonitrile (3 ml) were warmed to reflux for 40 hours. The solvent was removed under reduced pressure and the crude product was dissolved in ethanol (4 ml). Sodium hydroxide (0.1 g) was added and the mixture was warmed to reflux for 1 hour. The solvent was removed under reduced pressure and the residue was partitioned between DCM and 2 M acetic acid. The organic layer was dried over sodium sulphate and the solvent was removed under reduced pressure. The residue was purified by chromatography (EtOAc: formic acid, 500:1) to give 61 mg (64%) of the title compound. NMR (500 MHz, CDC13): 0.86 (t, 3H), 0.92 (t, 3H), 1.0-1.05 (m, IH), 1.2-1.4 (m, 3H), 1.6- 1.75 (m, 2H), 1.85-1.95 (m, IH), 2.38-2.47 (m, IH), 3.45 (s, 2H), 4.5 (s, 2H), 6.17 (s, IH), 6.75 (d, IH), 6.86 (dd, IH), 7.37-7.5 (m, 5H), 7.64 (d, IH). Method 2
1 , 1 -Dioxo-3(RV3-butyl-3-ethyl-5-(Ry 5-phenyl-8-(N- ((R -α-rN-(t-butoxycarbonylmethvn carbamoyllbenzyl} carbamoylmethoxy)-2.3 ,4,5-tetrahydro- 1 ,4-benzothiazepine; and
1 a-Dioxo-3(S)-3-butyl-3-ethyl-5-rS)-5-phenyl-8-rN- (ffD-α-rN-rt-butoxycarbonylmethyl carbamoyllbenzyl>carbamoylmethoxy -2,3,4,5-tetrahvdro-l,4-benzothiazepine
(+-)-trans-l,l-Dioxo-3-butyl-3-ethyl-5-phenyl-8-(carboxymethoxy)-2,3,4,5-tetrahydro- 1,4-benzothiazepine (Method 1; 17.5 mg, 0.041 mmol) was dissolved in DCM (3 ml). 2,6- Lutidine (0.010 ml, 0.086 mmol), TBTU (16.4 mg, 0.051 mmol) and (R)-α-[N-(t- butoxycarbonylmethyl)carbamoyl]benzylamine (Method 4; 16.3 mg, 0.062 mmol) were added successively. The mixture was stirred for 1 hour at ambient temperature. The solution was concentrated and the crude product was purified by chromatography on silica using DCM/EtOAc (8/2) as eluent. The solvent was evaporated and the title products were obtained in 98% yield (27 mg). M/z: 678 (M+l).
Method 3
(R -N-Benzyloxycarbonyl-α-fN-ft-butoxycarbonylmethvDcarbamoyllbenzylamine
(2i?)-{[(Benzyloxy)carbonyl]amino}(phenyl)acetic acid (10 g, 35.0 mmol) and t- butylglycine hydrochloride (6.3 g, 37.4 mmol) were dissolved in DCM (200 ml) with 2,6- lutidine (8.2 ml, 70.4 mmol). After stirring 5 min at 0°C TBTU (12.4 g, 38.6 mmol) was added and stirring was continued for 1.5 hours at 0°C and 3.75 hours at room temperature.
The reaction mixture was washed with water (2 x 100 ml), dried (MgSO4) and purified with flash chromatography (DCM:EtOAc 7:1→5:1) to give the title compound (13 g, 94 %). ΝMR
(500 MHz, CDC13): 1.45 (s, 9H), 3.84 (d, IH), 4.00 (dd, IH), 5.10 (m, 2H), 5.28 (brs, IH),
6.13 (brs, IH), 6.23 (brs, IH), 7.30-7.44 (m, 10H).
Method 4
(R -α-[N-(t-Butoxycarbonylmethyl)carbamoyl1benzylamine
(R)-N-Benzyloxycarbonyl-α-[N-(t-butoxycarbonylmethyl)carbamoyl]benzylamine
(Method 3; 12.8 g, 32.2 mmol) was dissolved in EtOH (99%, 200 ml) and toluene (50 ml). Pd/C (10%, 0.65 g) was added and hydrogenation was performed at atmospheric pressure for
5.5 hours at room temperature. The reaction mixture was filtered through diatomaceous earth and the solvents were evaporated to give the title compound (8.4 g, 99 %). NMR (600 MHz, CDC13): 1.45 (s, 9H), 3.93 (m, 2H), 4.54 (s, IH), 7.31-7.42 (m, 5H), 7.51 (brs, IH).
Method 5 3,5-trα7w-l,l-Dioxo-3-ethyl-3-butyl-5-phenyl-7-bromo-8-(carboxymethoxy -2,3.4.5- tetrahydro- 1 ■,4-benzotbiazepine
The title compound was prepared as described in Method 6 starting from (+/-)-trans-7- bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-5-phenyl-l,4-benzothiazepin-8-ol 1,1-dioxide (WO96/05188; 81 mg, 0.18 mmol). The intermediate ethyl ester was obtained in 94% yield (m/z: 538(M) and 540(M+2)). The product was obtained in 50 mg (58%). NMR 0.75 (t, 3H), 0.95 (t, 3H), 1.2-1.45 (m, 6H), 1.75-1.9 (m, IH), 2.2-2.4 (m, IH), 3.35 (dd, 2H), 4.8 (s, 2H), 6.0 (s, IH), 6.8 (s, IH), 7.3-7.5 (m, 5H), 7.55 (s, IH); m/z: 510 (M) and 512 (M+2)2+.
Method 6 3,5-trans-l, l-Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(carboxymethoxy')-2,3,4,5- tetrahydro- 1 ,4-benzothiazepine
The title compound was prepared from 3,5-trøns-l,l-dioxo-3-ethyl-3-butyl-5-phenyl- 7-methylthio-8-hydroxy-2,3,4,5-tetrahydro-l,4-benzothiazepine (Method 7; 153 mg, 0.36 mmol) using the procedure described in Method 1. The intermediate ethyl ester was extracted between diluted HCl and DCM. The DCM phase was washed with brine, dried with Na2SO4 and concentrated. M/z 506. The crude product was dissolved in THF/H2O (3/1; 4 ml) and LiOH (22 mg, 0.91 mmol) was added. The mixture was stirred for 2h and the solvent was removed under reduced pressure. The crude product was purified using preparative HPLC. A gradient from 40% to 60% MeCN in 0.1 M ammonium acetate buffer was used as eluent. The MeCN was removed under reduced pressure and the remaining aqueous solution was acidified using 5% HCl and was then extracted with DCM. The DCM layer was dried with Na2SO4 and concentrated. The crude product was co-evaporated with diethyl ether. The obtained crystals were filtered off and dried. Mass: 158 mg (91%). NMR 0.75 (t, 3H), 0.9 (t, 3H), 1.1-1.7 (m, 6H), 1.7-1.9 (m, IH), 2.0 (s, 3H), 2.2-2.4 (m,lH), 3.3 (dd, 2H), 4.75 (s, 2H), 6.0 (s, IH), 6.4 (s, IH), 7.3-7.5 (m, 6H); m/z: 478. Method 7
3,5-trørø-l -Dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-hvdroxy-2,3,4.5-tetrahvdro-L4- benzothiazepine
(+/-)-trans-7-Bromo-3-butyl-3-ethyl-2,3,4,5-tetrahydro-8-methoxy-5-phenyl-l,4- benzothiazepine 1,1-dioxide (prepared according to WO 96/05188; 300 mg, 0.64 mmol) was dissolved in 5 ml DMF under N2(g)-atmosphere. Sodium thiomethylate (150 mg, 2.14 mmol) was added and the mixture was heated to 110°C for 2h.The solvent was removed under reduced pressure and the residue was extracted between 5% HCl and EtOAc. The organic phase was washed with brine, dried with Na2SO4 and concentrated. The product was purified using preparative HPLC. A gradient from 40% to 100% of MeCN in 0.1 M ammonium acetate buffer was used as eluent. Lyophilisation yielded 153 mg, 57%. M/z: 420.
Method 8
2-{[(2R -2-Amino-2-('4-hvdroxyphenyl ethanoyl]amino>ethanesulphonic acid N-Boc-(D)-4-hydroxyphenylglycine (1.00 g, 3.21 mmol) was dissolved in DMF (5 ml) and tetrabutylammonium famine (2.36 g, 6.42 mmol) was added together with additional DMF (5 ml). The resulting suspension was cooled on ice and TBTU (1.24 g, 3.85 mmol) was added. The ice bath was removed after 30 min and the mixture was stirred for 2 hours before it was filtered and concentrated. TFA in DCM (20%, 20 ml) was added and the reaction mixture was stirred over night. Ethanol (20 ml) was added and the solvents evaporated. The crude product was refluxed in ethanol (100 ml) for 1 hour. Filtration yielded the pure title compound as a white solid, 626 mg (71%). ΝMR (DMSO-d6): 2.4-2.6 (m, 2H), 3.2-3.4 (m, 2H), 4.79 (s, IH), 6.78 (d, 2H), 7.23 (d, 2H), 8.22 (t, IH), 8.4 (brs, 3H), 9.7 (s, IH).

Claims (23)

Claims
1. A compound of formula (I) :
(I) wherein:
One of R1 and R2 are selected from hydrogen, C1-6alkyl or C -6alkenyl and the other is selected from C1-6alkyl or C2-6alkenyl;
Ry is selected from hydrogen, hydroxy, C1-6alkyl, C1-4alkoxy and C1-6alkanoyloxy;
Rz is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl and N,N-(C1-6alkyl)2sulphamoyl; v is 0-5; one of R4 and R5 is a group of formula (IA):
(IA)
R3 and R6 and the other of R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1- alkoxy, C1- alkanoyl, C1- alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1- alkyl)2amino, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl and N,N-(C1-4alkyl)2sulphamoyl; wherein R3 and R6 and the other of R and R5 may be optionally substituted on carbon by one or more R16;
X is -O-, -Ν(R3)-, -S(O)b- or -CH(Ra)-; wherein Ra is hydrogen or C1-6alkyl and b is 0- 2; Ring A is aryl or heteroaryl; wherein Ring A is optionally substituted by one or more substituents selected from R ;
R7 is hydrogen, C1- alkyl, carbocyclyl or heterocyclyl; wherein R7 is optionally substituted by one or more substituents selected from R18;
R8 is hydrogen or C1-4alkyl; R9 is hydrogen or C1-4alkyl;
R10 is hydrogen, C1-4alkyl, carbocyclyl or heterocyclyl; wherein R10 is optionally substituted by one or more substituents selected from R19;
R11 is carboxy, sulpho, sulphino, phosphono, -P(O)(ORc)(ORd), -P(O)(OH)(ORc), -P(O)(OH)(Rd) or -P(O)(ORc)(Rd) wherein Rc and Rd are independently selected from C1-6alkyl; or Rπ is a group of formula (IB):
(IB) wherein:
Y is -N(RX)-, -N(Rx)C(O)-, -O-, and -S(O)a-; wherein a is 0-2 and Rx is hydrogen or C1-4alkyl;
R is hydrogen or C1-4alkyl;
R13 and R14 are independently selected from hydrogen, C1-6alkyl, carbocyclyl or heterocyclyl; wherein R13 and R14 may be independently optionally substituted by one or more substituents selected from R20; R15 is carboxy, sulpho, sulphino, phosphono, -P(O)(ORe)(ORf), -P(O)(OH)(ORe),
-P(O)(OH)(Re) or -P(O)(ORe)(Rf) wherein Re and Rf are independently selected from C1-6alkyl; or R15 is a group of formula (IC):
(IC) wherein:
R24 is selected from hydrogen or C1- alkyl; R25 is selected from hydrogen, C1-4alkyl, carbocyclyl, heterocyclyl or R27; wherein said
C1-4alkyl, carbocyclyl or heterocyclyl maybe independently optionally substituted by one or more substituents selected from R28;
R26 is selected from carboxy, sulpho, sulphino, phosphono, tetrazolyl, -P(O)(ORg)(ORh), -P(O)(OH)(ORg), -P(O)(OH)(Rg) or -P(O)(ORε)(Rh) wherein Rg and Rh are independently selected from C1-6alkyl; p is 1-3; wherein the values of R13 may be the same or different; q is 0-1; r is 0-3; wherein the values of R14 may be the same or different; m is 0-2; wherein the values of R10 maybe the same or different; n is 1-3; wherein the values of R7 may be the same or different; z is 0-3; wherein the values of R25 may be the same or different; R16, R17 and R18 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1- alkyl)2amino, C1- alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1-4alkyl)sulphamoyl and N,N-(C1- alkyl)2sulphamoyl; wherein R16, R17 and R18 may be independently optionally substituted on carbon by one or more R ;
R19, R20, R27 and R28 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1- alkyl, C -4alkenyl, C2-4alkynyl, C1-4alkoxy, C1- alkanoyl, C1- alkanoyloxy, N-(C1-4alkyl)amino, N,N-(C1-4alkyl)2amino, Cι-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N-(C1- alkyl)sulphamoyl, N,N-(C1-4alkyl)2sulphamoyl, carbocyclyl, heterocyclyl, sulpho, sulphino, amidino, (C1-4alkyl)3silyl, phosphono, -P(O)(ORa)(OR ), -P(O)(OH)(ORa), -P(O)(OH)(Ra) or -P(O)(ORa)(Rb), wherein Ra and Rb are independently selected from C1-6alkyl; wherein R19 and R20 maybe independently optionally substituted on carbon by one or more R22;
R21 and R22 are independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxy, methylamino, dimethylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, methylthio, methylsulphinyl, mesyl, N-methylsulphamoyl and N,N-dimethylsulphamoyl; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
2. A compound of formula (I) as claimed in claim 1 wherein one of R1 and R2 is ethyl and the other is butyl or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
3. A compound of formula (I) as claimed in either of claims 1 or 2 wherein Ry is hydrogen or hydroxy or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
4. A compound of formula (I) as claimed in any one of claims 1-3 wherein v is 0 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
5. A compound of formula (I) as claimed in any one of claims 1-4 wherein R3 and R6 are hydrogen or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
6. A compound of formula (I) as claimed in any one of claims 1-5 wherein R4 is hydrogen, halo or C1-4alkylS(O)a wherein a is 0 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
7. A compound of formula (I) as claimed in any one of claims 1-6 wherein R5 is a group of formula (IA) (as depicted in claim 1); wherein X is -O-; Ring A is phenyl or 4-hydroxyphenyl;
R is hydrogen;
R8 is hydrogen;
R9 is hydrogen; R11 is carboxy; or R11 is a group of formula (IB) (as depicted above); wherein:
R12 is hydrogen;
R13 is hydrogen;
R15 is carboxy or sulpho; p is 1 or 2; q is O; r is 0; m is 0; and n is 1; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
8. A compound of formula (I) (as depicted above) wherein:
R1 and R2 are C1-4alkyl; v is 0;
Ry is hydrogen or hydroxy; R3 and R6 are hydrogen;
R4 is hydrogen, halo or C1- alkylS(O)a wherein a is 0;
R5 is a group of formula (I A) (as depicted above); wherein
X is -O-;
Ring A is aryl; wherein Ring A is optionally substituted by one or more substituents selected from R17;
R7 is hydrogen;
R8 is hydrogen;
R9 is hydrogen;
R11 is carboxy; or R11 is a group of formula (IB) (as depicted above); wherein: R12 is hydrogen;
R13 is hydrogen;
R15 is carboxy or sulpho; p is 1 or 2; q is O; r is 0; m is 0; n is 1; and
R17 is hydroxy; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
9. A compound of formula (I) selected from: l,l-dioxo-3(R)-3-butyl-3-ethyl-5-(R)-5-phenyl-8-[N-((R)-α-carboxybenzyl) carbamoylmethoxy] -2,3 ,4,5-tetrahydro- 1 ,4-benzothiazepine; l,l-dioxo-3(S)-3-butyl-3-ethyl-5-(S)-5-phenyl-8-[N-((R)-α-carboxybenzyl) carbamoylmethoxy]-2,3,4,5-tetraliydro-l,4-benzothiazepine; l,l-dioxo-3(R)-3-butyl-3-ethyl-5-(R)-5-phenyl-8-(N-{(R)-α-[N-(carboxymethyl)carbamoyl] benzyl} carbamoylmethoxy)-2,3 ,4,5-tetrahydro- 1 ,4-benzothiazepine; l,l-dioxo-3(S)-3-butyl-3-ethyl-5-(S)-5-phenyl-8-(N-{(R)-α-[N-(carboxymethyl)carbamoyl] benzyl} carbamoylmethoxy)-2,3 ,4,5-tetrahydro- 1 ,4-benzothiazepine;
3,5-trans- 1 , 1 -dioxo-3-ethyl-3-butyl-5-phenyl-7-bromo-8-(N- {(R)-α-[N-
(carboxymethyl)carbamoyl]berιzyl}carbamoyhnethoxy)-2,3,4,5-tetrahydro-l,4- benzothiazepine;
3,5-tran5-l,l-dioxo-3-(S)-3-ethyl-3-butyl-4-hydroxy-5-(S)-5-phenyl-7-bromo-8-(N-{(R)-α-
[N-(carboxymethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3 ,4,5-tetrahydro- 1 ,4- benzothiazepine
3,5-trαrø-l,l-dioxo-3-(R)-3-ethyl-3-butyl-4-hydroxy-5-(R)-5-phenyl-7-bromo-8-(N-{(R)-α- [N-(carboxymethyl)carbamoyl]beiizyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-l,4- benzothiazepine;
3,5-trarø-l,l-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-
(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-l,4- benzothiazepine; 3,5-trαrø-l,l-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-(2- sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-l,4- benzothiazepine ammonia salt; l,l-dioxo-3-(S)-3-ethyl-3-butyl-5-(S)-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-
(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-l,4- benzothiazepine diethylamine salt; and l,l-dioxo-3-(R)-3-ethyl-3-butyl-5-(R)-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-
(carboxymethyl)carbainoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-l,4- benzothiazepine diethylamine salt; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
10. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 -9, which process comprises of: Process 1): oxidising a benzothiazepine of formula (II):
(ii); Process 2): for compounds of formula (I) wherein X is -O-,-ΝRa or -S-; reacting a compound of formula (Ilia) or (Illb):
with a compound of formula (IV): (IN) wherein L is a displaceable group;
Process 3): reacting an acid of formula (Va) or (Vb):
(Va) (Vb) or an activated derivative thereof; with an amine of formula (VI):
(VI); Process 4): for compounds of formula (I) wherein R11 is a group of formula (IB); reacting a compound of formula (I) wherein R11 is carboxy with an amine of formula (VII):
(VII)
Process 5): for compounds of formula (I) wherein R11 is a group of formula (IB) and R15 is a group of formula (IC) reacting a compound of formula (I) wherein R15 is carboxy with an amine of formula (VIII):
(VIII)
Process 6) for compounds of formula (I) wherein one of R and RD are independently selected from C1-6alkylthio optionally substituted on carbon by one or more R16; reacting a compound of fomiula (IXa) or (IXb):
(IXa) (IXb) wherein L is a displaceable group; with a thiol of formula (X):
Rm-H (X) wherein Rm is Cι-6alkylthio optionally substituted on carbon by one or more R16; Process 7): for compounds of formula (I) wherein R11 is carboxy; deprotecting a compound of formula (XIa):
(XIa) or (Xlb):
(Xlb) wherein Rx together with the -OC(O)- group to which it is attached forms an ester; Process 8): for compounds of formula (I) wherein R11 is a group of formula (IB) and R15 is carboxy; deprotecting a compound of formula (Xlla):
(Xlla) or (Xllb):
(Xllb) wherein Rx together with the -OC(O)- group to which it is attached forms an ester; Process 9): for compounds of formula (I) wherein R11 is a group of formula (IB) and Y is -N(Rx)C(O)-; reacting an acid of formula (Xllla):
(Xllla) or (Xlllb):
(Xlllb) or an activated derivative thereof; with an amine of formula (XIV):
(XIV) or Process 10): for compounds of formula (I) wherein R11 is a group of formula (IB), R15 is a group of formula (IC) and R26 is carboxy; deprotecting a compound of formula (XVa):
(XVa) or (XVb):
(XVb) wherein Rx together with the -OC(O)- group to which it is attached forms an ester; and thereafter if necessary or desirable: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug.
11. A compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9 for use as a medicament.
12. A compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9 for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.
13. The use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.
14. The use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9, in the production of an IBAT inhibitory effect in a warm-blooded animal, such as man.
15. A method for producing an IBAT inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9.
16. A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9, in association with a pharmaceutically-acceptable diluent or carrier.
17. A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.
18. A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9, and a bile acid binder, in association with a pharmaceutically acceptable diluent or carrier.
19. A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9, and an HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and a bile acid binder in association with a pharmaceutically acceptable diluent or carrier.
20. A composition according to claim 17 or claim 19 wherein the HMG Co-A reductase inhibitor is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
21. A composition according to claim 17 or claim 19 wherein the HMG Co-A reductase inhibitor is rosuvastatin, or a pharmaceutically acceptable salt thereof.
22. A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, as claimed in any one of claims 1 to 9 and a PPAR alpha and/or gamma agonist, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.
23. A composition according to claim 22 wherein the PPAR alpha and/or gamma agonist is (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy)phenyl]propanoic acid or a pharmaceutically acceptable salt thereof.
AU2002331927A 2001-09-07 2002-09-05 Benzothiazepine derivatives for the treatment of hyperlipidaemia Ceased AU2002331927B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0121621.7 2001-09-07
GBGB0121621.7A GB0121621D0 (en) 2001-09-07 2001-09-07 Chemical compounds
PCT/GB2002/004043 WO2003022825A1 (en) 2001-09-07 2002-09-05 Benzothiazepine derivatives for the treatment of hyperlipidemia

Publications (2)

Publication Number Publication Date
AU2002331927A1 true AU2002331927A1 (en) 2003-06-19
AU2002331927B2 AU2002331927B2 (en) 2008-02-21

Family

ID=9921649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002331927A Ceased AU2002331927B2 (en) 2001-09-07 2002-09-05 Benzothiazepine derivatives for the treatment of hyperlipidaemia

Country Status (19)

Country Link
US (1) US7125864B2 (en)
EP (1) EP1427713B1 (en)
JP (1) JP4494780B2 (en)
KR (1) KR20040031057A (en)
CN (1) CN1639140A (en)
AT (1) ATE454379T1 (en)
AU (1) AU2002331927B2 (en)
BR (1) BR0212344A (en)
CA (1) CA2459457A1 (en)
DE (1) DE60235019D1 (en)
ES (1) ES2337559T3 (en)
GB (1) GB0121621D0 (en)
IL (1) IL160689A0 (en)
MX (1) MXPA04002189A (en)
NO (1) NO20040954L (en)
NZ (1) NZ531797A (en)
UY (1) UY27437A1 (en)
WO (1) WO2003022825A1 (en)
ZA (1) ZA200401796B (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
RU2305681C2 (en) 2001-09-08 2007-09-10 Астразенека Аб Benzothiadiazepine derivatives and method for production thereof (variants)
SE0104333D0 (en) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
DK1517883T3 (en) * 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
KR20070026392A (en) * 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 Novel benzothiazepine and benzothiepine compounds
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
AR057828A1 (en) * 2005-09-29 2007-12-19 Astrazeneca Ab COMPOUNDS DERIVED FROM AZETIDINE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
DE102006053635B4 (en) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Novel benzyl-substituted 1,4-benzothiepine-1,1-dioxide derivatives, drugs containing these compounds and their use
CN101790512A (en) * 2007-03-08 2010-07-28 阿尔比里奥公司 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
JO3131B1 (en) 2010-04-27 2017-09-20 Glaxosmithkline Llc Chemical Compounds
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
BR112013010157B1 (en) 2010-11-08 2020-02-04 Albireo Ab ibat inhibitors, their uses, and pharmaceutical composition and combinations
AU2011326872C1 (en) 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
CN104023718B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of high cholemia and cholestatic liver disease
KR102051030B1 (en) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
CN106659726A (en) 2014-06-25 2017-05-10 Ea制药株式会社 Solid preparation, and method for preventing or reducing discoloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
JP6954927B2 (en) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ Oral cholestyramine preparation and its use
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
ES2874669T3 (en) 2016-02-09 2021-11-05 Albireo Ab Oral formulation of cholestyramine and its use
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
JP2020530448A (en) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ Cholestyramine granules, oral cholestyramine preparations, and their use
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (en) 2018-06-05 2023-06-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112262130A (en) 2018-06-20 2021-01-22 阿尔比里奥公司 Crystal modification of odexibart
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
MX2021008981A (en) 2019-02-06 2021-09-08 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators.
CN113453753A (en) 2019-02-06 2021-09-28 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3129827A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
PL4069360T3 (en) 2019-12-04 2024-04-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AR120682A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
CN114786772B (en) 2019-12-04 2024-04-09 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
JP2023504644A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TW202134220A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
PT4069360T (en) 2019-12-04 2024-03-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134222A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541A1 (en) 2020-08-03 2023-06-07 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (en) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900757A (en) 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
JPH05186357A (en) 1991-12-31 1993-07-27 Shigeo Ochi Absorption-inhibitory means for digested product of food/ beverage
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
JP3304093B2 (en) 1994-09-13 2002-07-22 モンサント カンパニー Novel benzothiepines with inhibitory activity on ileal bile acid transport and taurocholate absorption
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
WO1997033882A1 (en) 1996-03-11 1997-09-18 G.D. Searle And Co. Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
EP0971744A2 (en) 1997-03-11 2000-01-19 G.D. SEARLE & CO. COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
ATE242258T1 (en) 1997-03-14 2003-06-15 Aventis Pharma Gmbh HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDE
AUPO763197A0 (en) 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
RU2236406C2 (en) 1997-12-19 2004-09-20 Г.Д. Серл Энд Ко. Method for preparing enantiomerically enriched tetrahydrobenzothiepine oxides
GB9800428D0 (en) * 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (en) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds
JP2002533414A (en) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー Combination of ileal bile acid transport inhibitors and bile acid sequestrants for cardiovascular applications
IL143947A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
WO2000038725A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
NZ512536A (en) 1998-12-23 2003-11-28 G Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
NZ512533A (en) 1998-12-23 2004-02-27 G A combination of IBAT inhibitor and nicotinic acid derivative to treat hypercholesterolemia, hyperlipidemic or atherosclerotic conditions
AU3694600A (en) 1999-02-12 2000-08-29 G.D. Searle Llc Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE19916108C1 (en) 1999-04-09 2001-01-11 Aventis Pharma Gmbh 1,4-Benzothiazepine-1,1-dioxide derivatives substituted with sugar residues, process for their preparation and their use
SE9901387D0 (en) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) * 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
WO2001060807A1 (en) 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
SE0000772D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US20020061888A1 (en) 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (en) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
RU2305681C2 (en) 2001-09-08 2007-09-10 Астразенека Аб Benzothiadiazepine derivatives and method for production thereof (variants)
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use

Similar Documents

Publication Publication Date Title
EP1427713B1 (en) Benzothiazepine derivatives for the treatment of hyperlipidemia
EP1427718B1 (en) Benzothiepine ileal bile acid transport inhibotors
US8067584B2 (en) Benzothiazepine derivatives
AU2002331927A1 (en) Benzothiazepine derivatives for the treatment of hyperlipidaemia
EP1501813B1 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
EP1427423B9 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
EP1430040B1 (en) Benzothiazepine derivatives
US20040067933A1 (en) Chemical compounds
US20050222120A1 (en) Peptides derivatives comprising thiazepine group for the treatment of hyperlipidermic conditions
AU2002329387A1 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
AU2002329386A1 (en) Benzothiepine ileal bile acid transport inhibitors
AU2002321579A1 (en) Benzothiazepine derivatives